Currently, inhibitors targeting IDO1 are being explored in clinical trials with the aim to undermine the immunosuppressive environment it creates, thereby enhancing anti-tumor immune responses and potentially improving the prognosis in various cancers [23]. This evidence concerns the gene IDO1 and neoplasm.